International Clinical Trial: Neoadjuvant Study of Vebreltinib for Resectable Stage IIA-IIIB (N2) NSCLC with MET Exon 14 Skipping Mutation

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128752) titled 'Neoadjuvant Study of Vebreltinib for Resectable Stage IIA-IIIB (N2) NSCLC with MET Exon 14 Skipping Mutation' on July 24.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: Resectable stage IIA-IIIB (N2) non-small cell lung cancer (NSCLC) with c-MET exon 14 skipping mutation

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-07-24

Target Sample Size: experimental group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=333765

Disclaimer: Curated by H...